Ignite Creation Date:
2025-12-24 @ 10:21 PM
Ignite Modification Date:
2026-01-02 @ 5:31 PM
Study NCT ID:
NCT06839235
Status:
RECRUITING
Last Update Posted:
2025-12-24
First Post:
2025-02-17
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase 1/2 Study of ABO-101 in Primary Hyperoxaluria Type 1 (redePHine)
Sponsor:
Arbor Biotechnologies
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-06-16
Start Date Type:
ACTUAL
Primary Completion Date:
2029-03
Primary Completion Date Type:
ESTIMATED
Completion Date:
2043-02
Completion Date Type:
ESTIMATED
First Submit Date:
2025-02-17
First Submit QC Date:
None
Study First Post Date:
2025-02-21
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-23
Last Update Post Date:
2025-12-24
Last Update Post Date Type:
ACTUAL